rethinkTHC Search
Menu
Study breakdown

Anandamide Shows Stronger Pain-Blocking Effects Than 2-AG on Migraine-Related Nerve Fibers in Mice

Animal StudyPreliminary evidence
The takeaway

In mouse meningeal nerve preparations, anandamide (AEA) produced stronger and longer-lasting suppression of pain-related nerve firing than 2-AG, suggesting FAAH inhibitors may be a promising migraine target.

Neuroscience researchers studying migraine mechanisms and pharmaceutical developers targeting the endocannabinoid system.

AEA suppressed high-amplitude nerve fibers firing above 10 Hz

What the researchers found

AEA reduced meningeal nerve firing more profoundly and for longer than 2-AG. AEA briefly activated slow-firing fibers (1-2 Hz), then persistently suppressed fast-firing fibers (>10 Hz). Only AEA inhibited subsequent capsaicin-induced firing. Mouse meninges showed higher FAAH activity and lower endogenous AEA levels.

Why it matters

This study provides mechanistic evidence that boosting AEA through FAAH inhibition could reduce migraine-related nerve activation, offering a specific target rather than broad cannabinoid receptor activation.

The numbers in context

AEA suppressed fibers firing >10 Hz; briefly activated fibers at 1-2 Hz; endogenous AEA levels lower than 2-AG; FAAH activity higher than MAGL in meninges.

How the study worked

Ex vivo electrophysiological recordings from C57BL/6J mouse hemiskull preparations. 10 uM AEA or 2-AG applied with 50 mM KCl stimulation. Clustering and spectral analysis. LC-MS/MS measured endogenous enzyme activity and endocannabinoid levels.

What this study cannot tell us

Ex vivo mouse preparation. Single concentrations tested. Results may not translate to human meningeal physiology. Does not test FAAH inhibitors directly.

How to read the evidence

Rigorous ex vivo methodology with multiple analytical approaches, but animal tissue study without in vivo validation.

When this study was published

2025 study presenting novel mechanistic data on endocannabinoids and meningeal pain signaling.

The bigger picture

This study narrows the endocannabinoid focus to AEA and FAAH specifically for migraine, suggesting peripheral FAAH inhibition as a strategy that could avoid central side effects.

Questions still open

  • Would FAAH inhibitors reduce migraine frequency in clinical trials?
  • Do these AEA effects translate to human tissue?

Common questions

Could endocannabinoids treat migraines?
This mouse study suggests boosting anandamide through FAAH inhibition could reduce migraine-related nerve firing. Clinical testing is still needed.
What is the difference between AEA and 2-AG?
Both are endocannabinoids, but AEA had stronger, longer-lasting effects on suppressing meningeal pain nerve firing in this study.

Read the original research

Differential inhibitory effects of endocannabinoids on neuronal firing of mouse meningeal afferents.

The journal of headache and pain, 26(1), 112

Citation

Krivoshein, Georgii; Della Pietra, Adriana; Savinainen, Juha; van den Maagdenberg, Arn M J M; Giniatullin, Rashid. (2025). Differential inhibitory effects of endocannabinoids on neuronal firing of mouse meningeal afferents.. The journal of headache and pain, 26(1), 112. https://doi.org/10.1186/s10194-025-02041-z

Explore the wider topic